Top

Published in:

01-12-2002 | Original Research Article

Pharmacokinetics of Ciprofloxacin as a Tool to Optimise Dosage Schedules in Community Patients

Authors: M. Dolores Sánchez Navarro, Carlos Coloma Milano, Aránzazu Zarzuelo Castañeda, M. Luisa Sayalero Marinero, Dr Amparo Sánchez-Navarro

Published in: Clinical Pharmacokinetics | Issue 14/2002

Abstract

Objective

To evaluate the dosage regimens of ciprofloxacin prescribed for outpatients by applying the principles of antibacterial therapy.

Design

Retrospective analysis of prescription and demographic data.

Setting

Community pharmacy in Valladolid, Spain.

Patients

Fifty male and female patients aged 18–93 years and with bodyweight 41–95kg.

Methods

Prescribed dosage regimen, age, weight, height, type of infection, comorbidity and coadministered drugs were recorded for each patient. Plasma concentration curves were simulated from literature values of the pharmacokinetic parameters of the drug and the age and weight of the patients. Urine concentrations were estimated from simulated plasma concentrations, literature values of renal clearance and an average urinary flow rate of 2 L/day. The potential efficacy of the prescribed treatment was evaluated from the ratio of the simulated peak plasma concentration (C_max) to the literature value of the minimum inhibitory concentration (MIC) for the bacterium most probably responsible for the infection (C_max/MIC). The ratio of area under the plasma concentration-time curve over 24 hours to MIC (AUC₂₄/MIC) was also estimated for non-urinary infections.

Results

Demographic variables such as age or bodyweight do not seem to be taken in consideration when ciprofloxacin is prescribed, at least in the patients considered here, leading to wide interindividual variability in plasma concentrations. This may not be relevant for urinary infections, since ciprofloxacin concentrates in the urine, leading to high C_max/MIC ratios in all patients. Simulated plasma concentration-time curves revealed consistent underdosing for systemic infections in young patients over 60kg, for whom the plasma concentrations achieved led to C_max/MIC and AUC₂₄/MIC ratios lower than those associated with clinical efficacy and minimal spread of bacterial resistance.

Conclusions

The standard regimen of ciprofloxacin 250mg every 12 hours prescribed for urinary infections may not be the best choice, since a more convenient regimen of 500mg once daily leads to a higher C_max/MIC ratio, which is associated with a more significant postantibiotic effect and higher efficacy of fluoroquinolones. For non-urinary infections, the age and weight of patients should be taken into account to achieve optimum plasma concentrations.

Levy SB. Antibiotic availability and use: consequences to man and his environment. J Clin Epidemiol 1991; 44 Suppl. II: S83–7CrossRef

Baquero F, Martínez Beltrán J, Loza E. A review of antibiotic resistance patterns of Streptococcus pneumoniae in Europe. J Antimicrob Chemother 1991; 28 Suppl. C: 31–8PubMedCrossRef

Ruiz Bremon A, Ruiz-Tovar M, Perez Gorricho B, et al. Non-hospital consumption of antibiotics in Spain: 1987–1997. J Antimicrob Chemother 2000; 45: 395–400CrossRef

Schentag JJ, Ballow CH, Paldino JA, et al. Dual individualization with antibiotics: integrated antibiotic management strategies for use in hospitals. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics. 3rd ed. Vancouver (WA): Applied Therapeutics Inc., 1992; 17: 1–20

Bouvier D’Ivoire MIJ, Mire PH. Dosage regimens of antibacterials: implications of a pharmacokinetic/pharmacodynamic model. Clin Drug Invest 1996; 11: 229–39CrossRef

Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1–10PubMedCrossRef

Li RC, Zhu M, Schentag JJ. Achieving an optimal outcome in the treatment of infections: the role of clinical pharmacokinetics and pharmacodynamics of antimicrobials. Clin Pharmacokinet 1999; 37: 1–16PubMedCrossRef

Baquero F. Antibiotic resistance in Spain: what can be done?. Task force of the General Directorate for Health Planning of the Spanish Ministry of Health. Clin Infect Dis 1996; 23: 819–23PubMedCrossRef

Doern GV. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am J Med 1995; 99 Suppl. 6B: S3–7CrossRef

10.

Jalal S, Ciofu O, Hoiby N, et al. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 2000; 44(3): 710–2PubMedCrossRef

11.

Goettsch W, van Pelt W, Nagelkerke N, et al. Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in the Netherlands. J Antimicrob Chemother 2000; 46(2): 223–8PubMedCrossRef

12.

Yamaguchi K, Miyazaki S, Kashitani F, et al. Activities of antimicrobial agents against 5180 clinical isolates obtained from 26 medical institutions during 1998 in Japan. Levofloxacin. Jpn J Antibiot 2000; 53(6): 387–408

13.

Wolfson JS, Hooper DC. The fluoroquinolones: structures, mechanisms of action and spectra of activity in vitro. Anti-microb Agents Chemother 1985; 28(4): 581–6CrossRef

14.

Campoli-Richards DM, Monk JP, Price A, et al. Ciprofloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1988; 35: 373–447PubMedCrossRef

15.

Grump B, Wise R, Dent J. Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother 1983; 24(5): 784–6CrossRef

16.

González MA, Uribe F, Moisen SD, et al. Multiple dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 1984; 26: 741–4PubMedCrossRef

17.

Fung-Tomc J, Minassian B, Kolek B, et al. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. J Antimicrob Chemother 2000; 45: 437–46PubMedCrossRef

18.

Aminimanizani A, Beringer P, Jelliffe R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin Pharmacokinet 2001; 40(3): 169–87PubMedCrossRef

19.

Sánchez-Navarro A, Sánchez Recio MM. Basis of anti-infective therapy: pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualisation. Clin Pharmacokinet 1999; 37: 289–304PubMedCrossRef

20.

MacGowan A, Rogers C, Bowker K. The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolones dosing regimens. J Antimicrob Chemother 2000; 46: 163–70PubMedCrossRef

21.

Sanchez-Recio MM, Colino CI, Sanchez-Navarro A. A retrospective analysis of pharmacokinetic/pharmacodynamic indices as indicators of the clinical efficacy of ciprofloxacin. J Antimicrob Chemother 2000; 45: 321–8PubMedCrossRef

22.

Sánchez-Navarro A, Colino CI, Sánchez Recio MM. A retrospective analysis of pharmacokinetic-pharmacodynamic parameters as indicators of the clinical efficacy of ceftizoxime. Clin Pharmacokinet 2001; 40(2): 125–34PubMedCrossRef

23.

Hyatt JM, Nix DE, Schentag JJ. Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus and Pseudomonas aeruginosa for which MICs are similar. Anti-microb Agents Chemother 1994; 32(12): 2730–7CrossRef

24.

Hyatt JM, Mckinnon PS, Zimmer GS, et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Clin Pharmacokinet 1995; 28: 143–60PubMedCrossRef

25.

Forrest A, Chodosh S, Amantea MA, et al. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1997; 40 Suppl. A: 45–57PubMedCrossRef

26.

Wagner JG. Farmacocinética clínica. Barcelona: Reverté SA, 1983: 129–74

27.

LeBel M, Barbeau G, Bergeron MG, et al. Pharmacokinetics of ciprofloxacin in elderly subjects. Pharmacotherapy 1986; 6(2): 87–91PubMed

28.

AbbottBase pharmacokinetic system. Abbott Park (IL): Abbott Laboratories, Diagnostic Division, 1991

29.

Sánchez Navarro MD, Sayalero Marinero ML, Sánchez Navarro A. Pharmacokinetic/pharmacodynamic modelling of ciprofloxacin 250mg/12 versus 500mg/24h. J Antimicrob Chemother 2002; 50: 67–72CrossRef

30.

Davis R, Markham A, Balfour J. Ciprofloxacin: an updated review of it pharmacology, therapeutic efficacy and tolerability. Drugs 1996; 51: 1019–74PubMedCrossRef

31.

Forrest A, Ballow C, Nix D, et al. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother 1993; 37: 1065–72PubMedCrossRef

32.

Jelliffe R, Schumtzky A, Bayard D, et al. Model-based, goal-oriented, individualised drug therapy: linkage of population modelling, new ‘multiple model’ dosage design, Bayesian feedback and individualised target goals. Clin Pharmacokinet 1998; 34: 57–77PubMedCrossRef

Title: Pharmacokinetics of Ciprofloxacin as a Tool to Optimise Dosage Schedules in Community Patients
Authors: M. Dolores Sánchez Navarro
Carlos Coloma Milano
Aránzazu Zarzuelo Castañeda
M. Luisa Sayalero Marinero
Dr Amparo Sánchez-Navarro
Publication date: 01-12-2002
Publisher: Springer International Publishing
Published in: Clinical Pharmacokinetics / Issue 14/2002
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI: https://doi.org/10.2165/00003088-200241140-00005

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Pharmacokinetics of Ciprofloxacin as a Tool to Optimise Dosage Schedules in Community Patients

Abstract

Objective

Design

Setting

Patients

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Design

Setting

Patients

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 14/2002

Pharmacokinetic and Pharmacodynamic Considerations When Treating Patients with Sepsis and Septic Shock

Antiretroviral Pharmacokinetics in the Paediatric Population

Interindividual Variability of the Clinical Pharmacokinetics of Methadone

Interactions Between Antiretroviral Drugs and Drugs Used for the Therapy of the Metabolic Complications Encountered During HIV Infection